The CHMP also concluded that, after 18 months of treatment, the benefit seen with Leqembi on CDR-SB – a 1.21-point increase with the drug versus a 1.66-point rise with placebo – represented a ...
the U.S. Food and Drug Administration (FDA) issued a notable approval for LEQEMBI® (lecanemab-irmb), the first medicine to slow the rate of cognitive decline in certain patients with early ...